Precede Biosciences
Biotechnology company developing a first-in-class liquid biopsy platform focused on enabling access to therapeutically actionable disease-defining transcriptional biology.
Website
https://www.precedebio.comLocation
San Diego, California, USA
Founded
2021
Investors
1
Categories
liquid-biopsy, diagnostics, transcriptomics, precision-medicine, biotech
Notes
Precede Biosciences is developing a first-in-class liquid biopsy platform that enables access to therapeutically actionable transcriptional biology. The company's approach focuses on analyzing RNA from blood samples to understand disease mechanisms and guide treatment decisions.
By focusing on transcriptional biology rather than just genetic mutations, Precede's platform can provide insights into dynamic disease processes and therapy responses.
Team
- Leadership team with expertise in liquid biopsy and precision medicine
Additional Research Findings
- Founded in 2021 in San Diego, California
- Focus on liquid biopsy and transcriptomics
- RNA-based approach to precision medicine
- Complementary to DNA-based liquid biopsy technologies
- Potential applications in oncology and other diseases
- Targeting therapeutically actionable insights
- Part of growing liquid biopsy diagnostics market
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |